These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35909336)

  • 1. Clinical severity scores as a guide for prediction of initial treatment responses in pemphigus and pemphigoid patients.
    Tanaka R; Kurihara Y; Egami S; Saito Y; Ouchi T; Funakoshi T; Takahashi H; Umegaki-Arao N; Kubo A; Tanikawa A; Amagai M; Yamagami J
    J Dermatol; 2023 Feb; 50(2):203-211. PubMed ID: 35909336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
    Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
    Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results.
    Kamata A; Kurihara Y; Funakoshi T; Takahashi H; Kuroda K; Hachiya T; Amagai M; Yamagami J
    Br J Dermatol; 2020 May; 182(5):1221-1227. PubMed ID: 31330562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody.
    Clapé A; Muller C; Gatouillat G; Le Jan S; Barbe C; Pham BN; Antonicelli F; Bernard P
    Front Immunol; 2018; 9():479. PubMed ID: 29662486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcomes of bullous pemphigoid patients with versus without oral prednisolone treatment.
    Ujiie I; Iwata H; Yoshimoto N; Izumi K; Shimizu H; Ujiie H
    J Dermatol; 2021 Apr; 48(4):502-510. PubMed ID: 33600037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid.
    Fujio Y; Kojima K; Hashiguchi M; Wakui M; Murata M; Amagai M; Yamagami J
    J Dermatol Sci; 2017 Mar; 85(3):208-215. PubMed ID: 28012821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
    van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
    JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary habits in Japanese patients with bullous pemphigoid: low intake of retinol.
    Uozumi T; Serizawa N; Hagino T; Morita T; Mizuno M; Ichiyama S; Hoashi T; Saeki H; Matsuda H; Nakagawa K; Mitsui H; Kanda N
    Eur J Dermatol; 2023 Aug; 33(4):394-403. PubMed ID: 37823490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue eosinophil levels as a marker of disease severity in bullous pemphigoid.
    Gore Karaali M; Koku Aksu AE; Cin M; Leblebici C; Kara Polat A; Gurel MS
    Australas J Dermatol; 2021 May; 62(2):e236-e241. PubMed ID: 33748980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.
    Sadik CD; Rashid H; Hammers CM; Diercks GFH; Weidinger A; Beissert S; Schauer F; Fettiplace J; Thaçi D; Ngai Y; Nunn MA; Zillikens D; Horváth B
    JAMA Dermatol; 2022 Jun; 158(6):641-649. PubMed ID: 35507334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies.
    Mohebi F; Tavakolpour S; Teimourpour A; Toosi R; Mahmoudi H; Balighi K; Ghandi N; Ghiasi M; Nourmohammadpour P; Lajevardi V; Abedini R; Azizpour A; Nasimi M; Daneshpazhooh M
    BMC Dermatol; 2020 Oct; 20(1):13. PubMed ID: 33129291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.
    Masmoudi W; Vaillant M; Vassileva S; Patsatsi A; Quereux G; Moltrasio C; Abasq C; Prost-Squarcioni C; Kottler D; Kiritsi D; Litrowski N; Plantin P; Friedrichsen L; Zebrowska A; Duvert-Lehembre S; Hofmann S; Ferranti V; Jouen F; Joly P; Hebert V;
    Br J Dermatol; 2021 Jun; 184(6):1106-1112. PubMed ID: 33067805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus.
    Boulard C; Duvert Lehembre S; Picard-Dahan C; Kern JS; Zambruno G; Feliciani C; Marinovic B; Vabres P; Borradori L; Prost-Squarcioni C; Labeille B; Richard MA; Ingen-Housz-Oro S; Houivet E; Werth VP; Murrell DF; Hertl M; Benichou J; Joly P;
    Br J Dermatol; 2016 Jul; 175(1):142-9. PubMed ID: 26800395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center.
    Nakagawa Y; Toyoda M; Saito N; Kaneyama N; Shimizu T; Mabuchi T; Fukagawa M
    Intern Med; 2023 Jun; 62(12):1715-1722. PubMed ID: 36328578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune Skin Conditions: Autoimmune Blistering Disease.
    Helm M; Helm LA; Clebak KT; Foulke G
    FP Essent; 2023 Mar; 526():13-17. PubMed ID: 36913658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients.
    Lévy-Sitbon C; Barbe C; Plee J; Goeldel AL; Antonicelli F; Reguiaï Z; Jolly D; Grange F; Bernard P
    Dermatology; 2014; 229(2):116-22. PubMed ID: 25011586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Lesions in Autoimmune Bullous Diseases: An Overview of Clinical Characteristics and Diagnostic Algorithm.
    Rashid H; Lamberts A; Diercks GFH; Pas HH; Meijer JM; Bolling MC; Horváth B
    Am J Clin Dermatol; 2019 Dec; 20(6):847-861. PubMed ID: 31313078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome measures for autoimmune blistering diseases.
    Zhao CY; Murrell DF
    J Dermatol; 2015 Jan; 42(1):31-6. PubMed ID: 25558950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actigraphy-measured nocturnal wrist movements and assessment of sleep quality in patients with bullous pemphigoid: a pilot case-control study.
    Kalinska-Bienias A; Piotrowski T; Kowalczyk E; Lesniewska A; Kaminska M; Jagielski P; Kowalewski C; Wozniak K
    Clin Exp Dermatol; 2019 Oct; 44(7):759-765. PubMed ID: 30652344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.